Dr.CardioMD said:

Short answer: the data supports it for most people

I respect Dr.CardioMD perspective but I think this oversimplifies things a bit. Re: Okay who else cannot stop — the effect size varies considerably by population.

I am not saying Dr.CardioMD wrong entirely — just that the picture is more nuanced than a blanket statement. The SUSTAIN data specifically shows different outcomes in different metabolic phenotypes.

Relevant to Okay who else cannot stop — here is my latest bloodwork comparison:

Key improvements: A1C 7.2% → 5.3%, triglycerides 247 → 117 mg/dL, hsCRP 6.0 → 1.1 mg/L. All on tirzepatide for 15 months.

The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.

Thank you Dr.EndoIndy! This is incredibly helpful. Bookmarking for later. 🙏

Slightly tangential to Okay who else cannot stop but JessicaM_2024 reminded me — has the insurance landscape changed recently?

I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.

Moderator note: Reminder: nothing posted here constitutes medical advice. Consult your healthcare provider.

Tagging this for the weekly digest. 👍